Evidence map›Paper›PMID 15755765›Full record

Trial reportThe New England journal of medicine2005

Intensive lipid lowering with atorvastatin in patients with stable coronary disease.

John C LaRosa, Scott M Grundy, David D Waters, Charles Shear, Philip Barter, Jean-Charles Fruchart, Antonio M Gotto, Heiner Greten, John J P Kastelein, James Shepherd and 2 more

6 registry-linked trialsOpen access · bronzeAbstract readClinical TrialMulticenter StudyRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in The New England journal of medicine, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT01200056. Cited by 895 papers, 20 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
895citing papers in PubMed, 20 pooled it
290.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01200056 phase4completedstarted 2007, after this paper: background citation

A Prospective, Double-blinded, Randomised Study to Evaluate the Effects of Different Doses of Statin Treatment on Plaque Volume and Composition in Coronary Disease Determined by Virtual Histology Using Intravascular Ultrasound

Ran2007Enrolled40Registered outcomes2Posted comparisons0ConditionsCoronary Disease, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Ultrasonography, InterventionalArmsAtorvastatin 10mg versus 40mg.
PMID 15519006PMID 15249516PMID 15007110PMID 12114036PMID 12390948PMID 12176951PMID 10687795PMID 11277825PMID 11300468PMID 11368702PMID 11468198PMID 11584167other papers from this trial
Open the trial in the graph
NCT03073863 phase4completed

Statin Intensity, Achieved LDL Cholesterol, and Cardiovascular Outcome in Statin Therapy in Patients With Coronary Artery Disease (Post-hoc Study of TNT Trial)

Ran1998Enrolled10,001Registered outcomes3Posted comparisons0ConditionsCardiovascular DiseasesArmsAtorvastatin
Open the trial in the graph
NCT03696940 phase3unknown statusstarted 2018, after this paper: background citation

Estudio clínico Fase III Para Evaluar la Eficacia terapéutica en Pacientes Mexicanos Con Dislipidemia Mediante el Uso vía Oral de L-Carnitina + Atorvastatina Comparado Con Atorvastatina

Ran2018Enrolled120Registered outcomes6Posted comparisons0ConditionsCardiovascular Risk Factor, DyslipidemiasArmsAtorvastatin 10mg, L-Carnitine 500Mg Oral Tablet + Atorvastatin 10 mg
PMID 27046161PMID 25537708PMID 24793440PMID 24793441PMID 24793443PMID 16034009PMID 26939026PMID 17039901PMID 23190071PMID 19604523PMID 25915661PMID 19618992other papers from this trial
Open the trial in the graph
NCT06782243 nacompletedstarted 2024, after this paper: background citation

Comparison of High and Moderate Intensity Statins in Achieving the Target LDL-C Level After Acute Coronary Syndrome: Randomized Controlled Trial

Ran2024Enrolled190Registered outcomes10Posted comparisons0ConditionsAcute Coronary SyndromeArmsHigh-Intensity Statins, Moderate-Intensity Statins
PMID 15007110PMID 23736519PMID 21067804other papers from this trial
Open the trial in the graph
NCT00552747 phase4completednot on this mapstarted 2007, after this paper: background citation

The Effect of Fenofibrate on Endothelial Function and HDL in Patients With Coronary Heart Disease and LDL-C at Goal

TypeinterventionalSponsorNational Heart Institute, MexicoRan2007 to 2011Enrolled76ConditionsCoronary Heart Disease, HyperlipidemiaArmsfenofibrate, placebo
NCT01186289 nawithdrawnnot on this mapstarted 2010, after this paper: background citation

Statin Therapy To Limit Cognitive Dysfunction After Cardiac Surgery

TypeinterventionalSponsorDuke UniversityRan2010 to 2012Enrolled0ConditionsNeurocognitive DysfunctionArmsatorvastatin
3 · Its place in the literature

Who cites it

895 citing papers in PubMed, 20 syntheses or guidelines pooled it, 3,486 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. Prevalence of statin intolerance: a meta-analysis.European heart journal · 2022 · on this map
    Pooled it
  15. The promising novel therapies for familial hypercholesterolemia.Journal of clinical laboratory analysis · 2022
    Pooled it
  16. Pooled it
  17. Pooled it
  18. Pooled it
  19. Pooled it
  20. Pooled it

835 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 11 institutions in 6 countries.

John C LaRosaState University of New York Health Science Center, Brooklyn, NY 11203, USA.
Scott M Grundy
David D Waters
Charles Shear
Philip Barter
Jean-Charles Fruchart
Antonio M Gotto
Heiner Greten
John J P Kastelein
James Shepherd
Nanette K Wenger
Treating to New Targets (TNT) Investigators
Cornell University · USEmory University · USInstitut Pasteur de Lille · FRPfizer (United States) · USSan Francisco General Hospital · USState University of New York · USThe Heart Research Institute · AUThe University of Texas Southwestern Medical Center · USUniversität Hamburg · DEUniversity of Amsterdam · NLUniversity of Glasgow · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPrevious trials have demonstrated that lowering low-density lipoprotein (LDL) cholesterol levels below currently recommended levels is beneficial in patients with acute coronary syndromes. We prospectively assessed the efficacy and safety of lowering LDL cholesterol levels below 100 mg per deciliter (2.6 mmol per liter) in patients with stable coronary heart disease (CHD).

methodsA total of 10,001 patients with clinically evident CHD and LDL cholesterol levels of less than 130 mg per deciliter (3.4 mmol per liter) were randomly assigned to double-blind therapy and received either 10 mg or 80 mg of atorvastatin per day. Patients were followed for a median of 4.9 years. The primary end point was the occurrence of a first major cardiovascular event, defined as death from CHD, nonfatal non-procedure-related myocardial infarction, resuscitation after cardiac arrest, or fatal or nonfatal stroke.

resultsThe mean LDL cholesterol levels were 77 mg per deciliter (2.0 mmol per liter) during treatment with 80 mg of atorvastatin and 101 mg per deciliter (2.6 mmol per liter) during treatment with 10 mg of atorvastatin. The incidence of persistent elevations in liver aminotransferase levels was 0.2 percent in the group given 10 mg of atorvastatin and 1.2 percent in the group given 80 mg of atorvastatin (P<0.001). A primary event occurred in 434 patients (8.7 percent) receiving 80 mg of atorvastatin, as compared with 548 patients (10.9 percent) receiving 10 mg of atorvastatin, representing an absolute reduction in the rate of major cardiovascular events of 2.2 percent and a 22 percent relative reduction in risk (hazard ratio, 0.78; 95 percent confidence interval, 0.69 to 0.89; P<0.001). There was no difference between the two treatment groups in overall mortality.

conclusionsIntensive lipid-lowering therapy with 80 mg of atorvastatin per day in patients with stable CHD provides significant clinical benefit beyond that afforded by treatment with 10 mg of atorvastatin per day. This occurred with a greater incidence of elevated aminotransferase levels.

Indexed as

AdultAgedAlanine TransaminaseAnticholesteremic AgentsAtorvastatinCardiovascular DiseasesCholesterolCholesterol, LDLCoronary DiseaseDose-Response Relationship, DrugFemaleHeptanoic AcidsHumansHydroxymethylglutaryl-CoA Reductase InhibitorsIncidenceMaleAlanine TransaminaseAnticholesteremic AgentsAtorvastatinCholesterolCholesterol, LDLHeptanoic AcidsHydroxymethylglutaryl-CoA Reductase InhibitorsPyrrolesTriglycerides

Identifiers

PMID15755765
OpenAlexW2139168645

What Socratic holds

Texttitle and abstract
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.